Floatz logo

Therapeutic Asset Ratings

1,027 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Brentuximab Vedotin
Florid Follicular Hyperplasia PTLD
Yale UniversityP2B (60)
Brentuximab Vedotin
Hematopoietic And Lymphoid System Neoplasm
Yale UniversityP2B (60)
Brentuximab Vedotin
Post-Transplant Lymphoproliferative Disease
Yale UniversityP2B (60)
Datopotamab Deruxtecan
Biliary Tract Cancer
AstraZenecaP2B (60)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Cancer
Astellas Pharma Global Development, Inc.P2B (60)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Urethra Transitional Cell Carcinoma
National Cancer Institute (NCI)P2B (60)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Urethra Cancer
Emory UniversityP2B (60)
Immunoglobulin G1 [240-alanine,241-alanine], anti-(human folate receptor ?) (human monoclonal PRO1184 ?1-chain, complex with human monoclonal PRO1184 ?-chain, dimer, 214??,214???,226,226?,232,232?,235,235?-octakis(thioether) with N6-[39-[bis(1-deoxy-D-glucitol-1-yl)amino]-1-oxo-4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxanonatriacont-1-yl]-N2-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-L-lysyl-L-valyl-N5-(aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]carbonyl]oxy]methyl]phenyl]-L-ornithinamide
Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)
GenmabP2B (60)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide
Urinary System Neoplasm
Sichuan Baili Pharmaceutical Co., Ltd.P2B (60)
Inotuzumab Ozogamicin
Recurrent B Lymphoblastic Lymphoma
University of WashingtonP2B (60)
Inotuzumab Ozogamicin
Refractory B Lymphoblastic Lymphoma
University of WashingtonP2B (60)
Polatuzumab Vedotin
Mantle Cell Lymphoma
Czech Lymphoma Study GroupP2B (60)
Polatuzumab Vedotin
Primary Mediastinal Large B-Cell Lymphoma
SWOG Cancer Research NetworkP2B (60)
rc48-adc
Acute Myeloid Leukemia With Positive Minimal Residual Disease
SillaJen, Inc.P2B (60)
rc48-adc
Advanced Squamous Non-Small-Cell Lung Cancer
BeOne MedicinesP2B (60)
rc48-adc
Locally Advanced Prostate Cancer
Shanghai Changzheng HospitalP2B (60)
rc48-adc
Ovarian Cancer
Second Xiangya Hospital of Central South UniversityP2B (60)
Sacituzumab Tirumotecan
Small Cell Lung Carcinoma
Sichuan UniversityP2B (60)
Trastuzumab Deruxtecan
Colon Adenocarcinoma
Gruppo Oncologico del Nord-OvestP2B (60)
Trastuzumab Deruxtecan
Neoplasm
Lei ZhengP2B (60)
Trastuzumab Deruxtecan
Hormone Receptor-Positive Breast Cancer
National Cancer Institute (NCI)P2B (60)
Trastuzumab Deruxtecan
Invasive Breast Carcinoma
National Cancer Institute (NCI)P2B (60)
Trastuzumab Emtansine
Lymphoma
Memorial Sloan Kettering Cancer CenterP2B (60)
Trastuzumab Emtansine
Ovarian Carcinoma
OHSU Knight Cancer InstituteP2B (60)
Trastuzumab Emtansine
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer InstituteP2B (60)
Showing 151 to 175 of 1,027 assets
PreviousPage 7 of 42Next